XM does not provide services to residents of the United States of America.
R
R

RECSilicon

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Eiffage, Quilter, Ricardo

EUROPE RESEARCH ROUNDUP-Eiffage, Quilter, Ricardo June 3 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Eiffage, Quilter and Ricardo, on Monday. HIGHLIGHTS * Acciona Energia ANE.MC : Morgan Stanley raises to equalweight from underweight * Eiffage FOUG.PA : Goldman Sachs raises to buy from neutral * Quilter Plc QLT.L : JP Morgan raises to overweight from neutral * Ricardo Plc RCDO.L : Berenberg raises to buy from hold * St.
B
C
C
E
H
H
I
I
J
P
P
R
S
V
D
L
N

Carlsberg, Danske Bank, Teleperformance

EUROPE RESEARCH ROUNDUP- Carlsberg, Danske Bank, Teleperformance May 10 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Carlsberg, Danske Bank and Teleperformance, on Friday. HIGHLIGHTS * Carlsberg A/S CARLB.CO : HSBC raises target price to DKK 1040 from DKK 1030 * Danske Bank DANSKE.CO : HSBC cuts target price to DKK 231 from DKK 238 * Hermes HRMS.PA : Jefferies initiates coverage with buy rating; price target EUR 2,650 * Rathbone
3
A
A
A
B
B
B
B
B
C
C
C
C
D
F
G
G
H
I
K
L
M
P
P
R
S
S
S
T
V
W
Z
A
D
S
S

Italy's Recordati CEO: shareholder CVC committed to company long-term growth

BRIEF-Italy's Recordati CEO: shareholder CVC committed to company long-term growth May 9 (Reuters) - Recordati CEO Rob Koremans tells analysts: CVC, AS A SHAREHOLDER, IS VERY COMMITTED TO THE COMPANY'S LONG-TERM GROWTH M&A IS AN IMPORTANT PART OF OUR STRATEGY, VERY HAPPY IF THE NEXT DEAL COULD BE IN RARE DESEASE BUSINESS Further company coverage: R
R

Italy's Recordati confirms guidance after robust Q1 performance

Italy's Recordati confirms guidance after robust Q1 performance May 9 (Reuters) - Italian drug maker Recordati RECI.MI posted a 10.5% rise in its first-quarter core profit on Thursday and confirmed its guidance for 2024 and 2025. The company said it had seen a "robust performance... across all key geographies and products". Interest, taxes, depreciation and amortisation (EBITDA) rose to 244.0 million euros ($262 million) with a margin of 40.2% for the January-March quarter, the Milan-based compa
R

Recordati Q1 EBITDA Up To EUR 244.0 Mln

BRIEF-Recordati Q1 EBITDA Up To EUR 244.0 Mln May 9 (Reuters) - Recordati Industria Chimica e Farmaceutica SpA RECI.MI : Q1 EBITDA EUR 244.0 MILLION VERSUS EUR 220.8 MILLION YEAR AGO CONFIRMS GUIDANCE FOR 2024 AND 2025 Q1 ADJUSTED NET PROFIT EUR 163.7 MILLION VERSUS EUR 155.0 MILLION YEAR AGO Further company coverage: RECI.MI Reporting by Gdansk Ne
R

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.